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Treatment of end-stage renal disease in children: A 15-year expe-
rience. From 1964 to 1979, 154 children 1 to 16 years of age with
end-stage renal disease (ESRD) were treated in a regional pediat-
ric dialysis and transplant program. The incidence of ESRD was
1.6 per million total population per year. The survival rate of
children undergoing dialysis for an average of 10 months was
93%. After living donor kidney transplantation (LD), patient sur-
vival rates in 60 children were 89% at 5 years, 83% at 10 years,
and 74% at 15 years. After cadaver donor kidney transplantation
(CD), patient survival rates in 85 children were 70% at 5 and 10
years. LD kidney survival was 71% at 5 years, 55% at 10 years,
and 40% at 15 years, whereas CD kidney survival was 43% at 5
years and 31% at 10 years. The survival of first and second trans-
plants was similar. Patient and kidney survival have improved
since 1972. The survival rate of 26 children 1 to 5 years of age
was 46%, but patients with Wilms' tumor accounted for most of
the deaths. We attribute these favorable long-term results in chil-
dren to an integrated program of dialysis and transplantation
with special pediatric facilities.
Traitement de l'insuffisance rénale terminale chez l'enfant: 15
Ans d'expérience. De 1964 a 1979, 154 enfants de 1 a 16 ans at-
teints d'insuffisance rénale terminale (ESRD) ont été traités dans
le cadre d'un programme pédiatrique regional de dialyse et trans-
plantation. L'incidence de 1'ESRD a été de 1,6 par million de
population totale et par an. Le taux de survie d'enfants en dia-
lyse pendant une durée moyenne de 10 mois était de 93%. Après
transplantations avec des reins de donneurs vivants (LD), Ic taux
de survie chez 60 enfants était de 89% a 5 ans, 83% a 10 ans, et
74% a 15 ans. Après transplantations de reins de cadavres (CD),
le taux de survie chez 85 enfants était de 70% a 5 et a 10 ans. La
survie des reins de donneurs vivants était de 71% a 5 ans, 55% a
10 ans, et 40% a 15 ans, alors que Ia survie des reins de cadavres
était de 43% a 5 ans et 31% a 10 ans. La survie des premiers et
deuxièmes transplants a été semblable. La survie des malades et
des reins a été améliorée depuis 1972. Le taux de survie de 26
enfants âgés de 1 a 5 ans a été de 46% et Ia plupart des décès
sont ceux des malades atteints de tumeur de Wilm. Nous attri-
buons ces résultats a long terme favorables chez des enfants a un
programme de dialyse et de transplantation intégré assorti de
modalités pédiatriques particulières.
The first successful kidney transplant between
end-stage renal disease (ESRD) have been pro-
longed by the complementary use of these two
forms of treatment. The incidence and causes of
ESRD and the results of treatment in adults have
been described extensively, and there are reviews
of more limited experience in children [1—5]. At the
University of California, San Francisco, two renal
transplants were performed in children in 1964, and
a comprehensive, regional program for the care of
children with ESRD was initiated in 1966 [6—7]. In
cooperation with other physicians in the area, this
program has coordinated the care of all children
with ESRD in the well-defined geographic area of
Northern California-Northern Nevada. Dialysis and
transplantation have been performed in one center
with the same physicians and staff involved in both
forms of therapy. In the course of this experience,
the incidence of ESRD in children, the inter-
relationship of dialysis and transplantation in the
treatment regimen, and the outcome of treatment
over periods as long as 15 years have been defined.
Methods
This report considers children who were 1 to 16
years of age when they reached end-stage renal dis-
ease. Children who died with acute, potentially re-
versible, renal disease were not included. The in-
cidence of ESRD in this age group was determined
for the area of Northern California-Northern Ne-
vada from referrals to our center, which is the only
pediatric ESRD center in the area, and from a sur-
vey of adult dialysis units. Incidence is expressed as
nonidentical individuals was performed in 1959, and
the first program of chronic hemodialysis was
started the following year. In the two decades that
have ensued, the lives of thousands of patients with
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cases per million total population per year. The
mean population of the area during the study was
8.3 million.
One hundred fifty-four children were treated with
dialysis or transplantation, or both, in our center.
Eighty-three received dialysis in the pediatric out-
patient dialysis unit. One hundred forty-five re-
ceived renal transplants, 74 after dialysis in the pe-
diatric unit and 71 after short periods of inpatient
dialysis, dialysis in adult units, or without previous
dialysis. Followup of the 154 children was complete
in May, 1979, and is outlined in the section Out-
comes of Treatment. All deaths were included in
survival calculations even if the children had trans-
ferred to other dialysis or transplant programs.
Deaths of 2 children who returned to dialysis after
transplantation were calculated as transplant
deaths; one of these deaths occurred in the pediatric
dialysis program and was also calculated as a dial-
ysis death.
Patient and kidney survival rates after trans-
plantation were calculated by actuarial methods [8]
and expressed as cumulative survival curves. Al-
though survival rates were calculated for all years
during which at least 1 patient or kidney was at risk,
rates calculated from samples of less than 10 were
not considered to have clinical significance. Dif-
ferences between survival curves were determined
by the Breslow modification of the Wilcoxon test
[9].
Basic immunosuppression after transplantation
was azathioprine, 2 to 3 mg/kg, and prednisone, 2 to
4 mg/kg. with progressive reduction of the steroid
dose. Irradiation of the kidney, actinomycin D,
antilymphocyte globulin, and pulse doses of
methylprednisolone were also used during various
periods in the program. The use of methyl predniso-
lone was discontinued, and the amount of immuno-
suppression used to treat rejections was decreased
in September, 1972 [10]. Beginning in 1970, children
with good renal function 6 months after trans-
plantation were treated with alternate-day pred-
nisone [11].
Selection of living donor kidneys was based on
the results of HL-A typing and, after 1971, also on
the results of mixed lymphocyte culture (MLC) re-
actions [12]. Of the 60 donors of primary kidneys,
there were 50 parents, 7 siblings, of whom 4 were
HL-A identical, 2 grandparents, and 1 uncle. Recip-
ients of cadaver kidneys were selected on the basis
of HL-A typing, but all cadaver kidneys were used
regardless of the match. No 4-antigen-match cadav-
er transplants were performed.
Results
Incidence. The number of children 1 to 16 years
of age with ESRD from Northern California-North-
ern Nevada identified by year is shown in Table 1.
After 1967, the number was fairly constant until the
years 1975-1978 when more marked fluctuations oc-
curred. The mean incidence of ESRD for the years
1968-1978 was 1.58 per million. The mean incidence
in three age groups, 1 to 5, 6 to 10, and 11 to 15
years was 0.31, 0.42, and 0.87 per million, respec-
tively.
Treatment. After 1967, when the chronic dialysis
and cadaver transplant programs were established,
all children with ESRD were considered for treat-
ment, and no a priori selection criteria were used.
Children with malignancies, systemic diseases, and
mental retardation were treated. Only 3 children
were excluded; each was less than 6 years of age
and had severe physical and developmental retarda-
tion.
The age distribution of the 154 children who were
treated is shown in Fig. 1. The mean age was 10
years. The causes of renal failure are listed in Table
2. Children with systemic or "high-risk diseases"
who were treated included 9 with Wilms' tumor, 3
with cystinosis, and 2 with lupus erthematosus.
Dialysis. The mean duration of dialysis of the 83
children was 10 months (range, ito 60 months). Six
were treated with hemodialysis in the home, 4 with
peritoneal dialysis in the home, and the remainder
with hemodialysis in the center. Seventy four re-
ceived transplants and 14 of these returned to dial-
ysis after rejection. Four infants, 15 to 23 months of
age, were dialyzed for periods of 3 to 15 months.
There were six deaths; three caused by complica-
tions of Wilms' tumor and one each by vasculitis,
pneumonia, and liver failure. Four of the children
who died were less than 6 years of age. The survival
rate was 93%.
Transplantation. The survival rate of 60 children
who received first transplants from living donors
was 85%, and the survival rate of 85 children who
received first transplants from cadaver donors was
76%. The survival rate of all children treated with
dialysis, transplantation, or both, was 78%.
Patient-survival curves after transplantation are
shown in Fig. 2. After living-donor transplantation,
six of nine deaths occurred during the first 3 years,
and 1 patient died during the 12th year. The 2 chil-
dren who received transplants in 1964 were alive at
15 years, and the cumulative survival rate was 74%.
After cadaver-donor transplantation, all of the
deaths occurred during the first 5 years, and the cu-
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mulative survival rate thereafter was 70%. The dif-
ference between the curves was significant, P <
0.05.
The primary cause of death after transplantation
was infection (Table 3). Two children who rejected
kidneys died from uremia after the decision was
made not to undergo further treatment, and 2 chil-
dren undergoing dialysis after rejection died. There
was one death from Wilms' tumor, and 4 other chil-
dren with Wilms' tumor died of infection. Ten of the
deaths occurred in the group of 20 children who
were less than 6 years of age at transplantation. Sur-
vival rates calculated for three age groups, 1 to 5
years, 6 to 10 years, and 11 to 16 years, were 50%,
76%, and 88%, respectively.
Kidney survival curves are shown in Fig. 3 for 60
primary living-donor kidneys, 85 primary cadaver
kidneys, and 27 second kidneys, all but 3 of which
were cadaver kidneys. The survival rates of prima-
ry living donor kidneys were 86% at 1 year, 81% at 2
Table 1. Number of children with end-stage renal disease in
Northern California—Northern Nevada
1966 6 1971 11 1976 20
1967 5 1972 15 1977 9
1968 11 1973 12 1978 23
1969 13 1974 16





Table 2. Cause of renal failure
No. ofcases by age group
ito 6to Ilto
Disease 5 yr 10 yr 16 yr
Chronic glomerulonephritis 7 15 33
Obstructive uropathy 1 2 17
Dysplasia-hypoplasia 2 9 5
Pylonephritis 1 4 6
Wilms' tumor 9a
Medullary cystic disease — 1 8
Hemolytic-uremic syndrome 2 6 1
Congenital nephrosis 3 — —
Cystinosis — 3 —
Lupus nephritis — — 2
Anaphylactoid purpura nephritis — 1 1
Infantile polycystic kidneys — 1 1
Interstitial nephritis 1 — —
Hereditary syndromes
Renal-retinal dysplasia — — 4
Alport's — 1 3
Nail patella — — 1
Lawrence-Moon-Biedl — — 1
Charcot-Marie-Tooth — — 1
Jeune's — 1 —
Total 26 44 84
Seven bilateral, two unilateral
other kidney
with cortical necrosis of the
years, and 55% at 10 years, whereas the survival
rates of primary cadaver kidneys were 65% at 1
year, 55% at 2 years, and 31% at 10 years. The dif-
ference between the curves was significant, P <
0.02. The results of second transplants were similar
to the results of primary cadaver transplants. Five
third transplants were performed, and three were
functioning at followup. The cause of kidney loss in
surviving patients was immunologic rejection in all
but 3 patients; 2 children had recurrence of glomer-
ulonephritis, and 1 required nephrectomy following
spontaneous renal decapsulation.
The amount of immunosuppression used to treat
rejections was reduced in 1972. Following this
change, the 2-year patient survival improved from
89% to 100% for recipients of living donor kidneys
and 61% to 94% for recipients of cadaver kidneys.
Two-year cadaver-kidney survival also improved,
from 46% to 58%, but living-donor kidney survival
was unchanged.
Kidney survival was plotted on semilog paper for
all living donor kidneys and for all cadaver kidneys
for the years during which at least 10 kidneys were
at risk (Fig. 4). The fractional loss rates of both liv-
ing-donor kidneys and of cadaver kidneys were
quite constant after the second year, and survival
rates for these periods were indicated by lines of
regression. Survival half-life times calculated for






Fig. 1. Age distribution of patients.
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Fig. 2. Patient survival after transplantation. Numbers above the
line refer to patients at risk. Numbers in parentheses denote total
number of patients.
living-donor kidneys and 6.8 years for cadaver kid-
neys.
The most recent serum creatinine concentration
of each patient with a functioning kidney was
plotted as a function of time after transplantation
(Fig. 5). Of 38 children with kidneys functioning
more than 5 years, 28 had serum creatinine concen-
trations 1.5 mg!dl.
Outcomes of treatment. The status of each of the
154 children at followup was examined in relation to
the most recent treatment event—either the initia-
tion of dialysis or the most recent transplant (Fig.
6). Thirty-four children (22%) were dead, 26 (17%)
were undergoing dialysis, and 92 (60%) had func-
tioning kidneys.
Discussion
During the 15 years this program has been in op-
eration, dialysis and transplantation have evolved
from experimental treatments for a handful of chil-
Table 3. Cause of death, transplant
Fig. 3. Kidney survival after transplantation. Numbers are de-
fined in Fig. 2.
100
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Fig. 4. Kidney survival after transplantation, including second-
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Time after transplant, yr
Fig. 5. Most recent serum crealinine concentration of each pa-
lient with afunctioning kidney. = living donor kidneys, 0 =
cadaver kidneys.







17 Dialysis 76 Functioning kidneys
29 2nd Transplants
6 Dead
4 Dialysis 14 Functioning kidneys
5 3rd Transplants
2 Dialysis Functioning kidneys
34 (22%) 26 (17%) 93 (60%)
Fig. 6. Outcomes of treatment including results of second trans-
plants in other institutions. One patient discontinued dialysis af-
ter 15 months.
dren to accepted therapy for thousands. A number
of observations and conclusions pertinent to this
evolution can be drawn from our experience.
There are few reliable data on the incidence of
ESRD in children. Although incidence figures as
high as 3.5 per million have been derived from death
certificate data, alone [13] or in combination with a
physician-hospital survey [14], figures derived from
surveys of nephrology units have been lower—0.75
to 1.5 per million [15]. In the only other study as-
sessing sequential data from a population [16], the
incidence in children 0.5 to 16 years was 1.36 per
million.
In our program, there were yearly variations in
the number of children presenting with ESRD, but
the average for consecutive 2-year periods was fair-
ly constant over an 11-year period. It is likely that
some children with ESRD and severe congenital
anomalies, severe mental retardation, or systemic
illness were not referred, but these children are
rarely candidates for dialysis and transplantation,
and the incidence of ESRD of 1.6 per million is
probably a reasonable estimate in planning treat-
ment facilities for children. We did not encourage
referrals of infants less than a year of age, and the
incidence of ESRD and indications for treatment in
this age group remain to be defined.
The incidence of children entering treatment was
1.3 per million in the ito 14 age group. This is high-
er than the incidence in any European country ex-
cept the Netherlands [5], and reflects the fact that
patterns of referral to our center are well estab-
lished and may also reflect our policy of considering
all children for treatment regardless of size and un-
derlying disease.
The results of treatment were evaluated in terms
of patient survival and the success of the program in
maintaining children with functioning kidneys. Be-
cause most children received transplants after short
periods of dialysis, we could not compare long-term
survival with the two forms of treatment, but the 1-
year survival with dialysis, 90%, was comparable
to the 1-year survival after living-donor transplan-
tation, 93%, and cadaver donor transplantation,
86%. Children undergoing dialysis invariably had
complications of uremia and the treatment regimen,
however, whereas transplantation offered the po-
tential for return to a normal life, and children
and families all regarded a well-functioning trans-
plant as the ultimate goal of treatment.
The results were influenced by patient age and
renal disease. A large number of young children, I
to 5 years, were treated, and survival rates in these
children were lower than they were in older chil-
dren, a finding in agreement with reports from dial-
ysis [17] and transplant [18] registries but contrary
to the experience of another large transplant pro-
gram [19]. Of the 26 children in this age group, 9 had
Wilms' tumor as their underlying disease, however,
and they accounted for more than one half of the
deaths. When these children are excluded from cal-
culations, the survival rate in the 1 to 5 age group
after transplantation is 64%, and the survival rate of
all children after transplantation is 83%.
Despite treatment of high-risk patients, long-term
patient survival was good. Of 30 children who
started treatment more than 10 years ago, 20 (67%)
were alive at followup, 15 with functioning kidneys.
Eighty percent of children who received transplants
over a 15-year period were alive compared with
74% over a 10-year period in Minneapolis [1], 86%
over a 91/2-year period in Los Angeles [3], and 78%
over a 123/4-year period in Cincinnati [4]. In trans-
plant programs where most of the patients were
adults, survival was 61% over a 25-year period in
Boston [20] and 65% over a 133/4-year period in
Denver [21].
Kidney survival, 71% for living-donor kidneys
and 43% for cadaver kidneys at 5 years, was better
than that reported from the Transplant Registry [22]
and similar to that achieved at two of the pediatric
centers cited above [1, 3]. To predict survival
beyond the 15 years covered in this report, we used
the method of Opelz, Mickey, and Terasaki [23],
who showed that the fractional loss rates of both
living-donor kidneys and cadaver kidneys were
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constant after the second year and could be de-
scribed by half-life survival times. Projected kidney
survival for our patients was approximately 30% for
living donor kidneys and 10% for cadaver kidneys
at 20 years. This prediction of prolonged survival is
supported by the observation that most of the chil-
dren with kidneys functioning longer than 5 years
have serum creatinine concentrations 1.5 mg!dl.
In our experience, late graft loss has invariably
been preceded by chronic rejection and elevated
serum creatinine concentrations beginning in the
first few years after transplantation.
Although the results expressed by survival
curves and projected survival times are favorable,
they are based on all transplants performed since
1964 and do not accurately reflect the chances for
success of transplants performed at the present
time. Patient survival and cadaver kidney survival
have improved markedly in recent years. Although
this improvement has been attributed to changes in
immunosuppressive therapy instituted in 1972 [10],
other changes, such as the introduction of the MLC
test, and the fact that the last transplant for Wilms'
tumor was performed in 1971, may have also played
a role. It is also likely that some of the difference in
results before and after 1972 reflects gradual im-
provement from accumulated experience rather
than specific changes in the transplant regimen.
Our experience emphasizes the benefits derived
when living-donor rather than cadaver kidneys are
used for transplantation. Not only were patient and
kidney survival better for recipients of living-donor
kidneys, but fewer children with functioning living-
donor kidneys, 18%, had serum creatinine concen-
trations > 1.5 mgldl at followup than did children
with functioning cadaver kidneys, 29%. Because
good renal function is the criterion for initiating al-
ternate-day prednisone therapy in our program,
children with living-donor kidneys were more likely
to receive the benefits of this regimen, including
normal growth [11], than were children with cada-
ver kidneys.
We attribute the favorable results in children to
an integrated program of dialysis and trans-
plantation with special facilities for children. Be-
cause the numbers of children with ESRD are
small, we, as well as others, have been able to treat
all children in a region in a single facility. The same
physicians and other health care personnel have
been involved in both forms of therapy. Transitions
between dialysis and transplantation have been fa-
cilitated, and children with multiple rejection epi-
sodes after transplantation have electively returned
to dialysis rather than undergoing prolonged high-
dose immunosuppressive therapy. The com-
plementary use of the two treatments has contrib-
uted to low mortality and a high rate of retransplan-
tation, and 64% of recipients over a 15-year period
have survived with functioning grafts. These re-
sults, and those from other pediatric programs,
demonstrate that dialysis and transplantation are ef-
fective treatments which can extend life and pro-
vide long-term benefits for children with ESRD.
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